Madrigal Pharmaceuticals (MDGL)
(Delayed Data from NSDQ)
$193.33 USD
-1.05 (-0.54%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $192.63 -0.70 (-0.36%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Cash flow Statements
Fiscal Year End for Madrigal Pharmaceuticals, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -373.63 | -295.35 | -241.85 | -202.24 | -83.95 |
Depreciation/Amortization & Depletion | 2.94 | 1.26 | 0.41 | 0.47 | 0.11 |
Net Change from Assets/Liabilities | -3.28 | 37.60 | 30.65 | 23.48 | 19.45 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 49.74 | 31.63 | 26.87 | 20.73 | 22.76 |
Net Cash From Operating Activities | -324.23 | -224.86 | -183.92 | -157.56 | -41.62 |
Property & Equipment | -1.48 | -0.22 | -0.21 | -0.33 | -0.17 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -501.04 | 206.90 | -4.85 | 160.11 | 30.88 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -502.52 | 206.69 | -5.06 | 159.78 | 30.71 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 260.19 | 264.34 | 171.24 | 5.09 | 0.24 |
Issuance (Repayment) of Debt | 335.29 | 50.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -0.36 | -0.89 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 595.12 | 313.45 | 171.24 | 5.09 | 0.24 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -231.63 | 295.28 | -17.74 | 7.31 | -10.68 |
Cash at Beginning of Period | 331.55 | 36.27 | 54.00 | 46.70 | 57.38 |
Cash at End of Period | 99.92 | 331.55 | 36.27 | 54.00 | 46.70 |
Diluted Net EPS | -19.99 | -17.23 | -14.63 | -13.09 | -5.45 |
Fiscal Year End for Madrigal Pharmaceuticals, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | -373.63 | -261.44 | -162.70 | -76.90 |
Depreciation/Amortization & Depletion | NA | 2.94 | 2.05 | 1.24 | 0.56 |
Net Change from Assets/Liabilities | NA | -3.28 | -19.79 | -20.14 | -18.98 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | 49.74 | 34.88 | 22.22 | 11.25 |
Net Cash From Operating Activities | NA | -324.23 | -244.30 | -159.38 | -84.07 |
Property & Equipment | NA | -1.48 | -0.44 | -0.10 | -0.04 |
Acquisition/ Disposition of Subsidiaries | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | NA | -501.04 | -139.95 | -190.49 | -186.83 |
Other Investing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | NA | -502.52 | -140.40 | -190.60 | -186.86 |
Uses of Funds
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | 260.19 | 50.56 | 45.91 | 17.90 |
Issuance (Repayment) of Debt | NA | 335.29 | 65.00 | 50.00 | 35.00 |
Increase (Decrease) Short-Term Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | -0.36 | -0.36 | -0.29 | -0.21 |
Net Cash from Financing Activities | NA | 595.12 | 115.20 | 95.62 | 52.69 |
Effect of Exchange Rate Changes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | NA | -231.63 | -269.49 | -254.35 | -218.24 |
Cash at Beginning of Period | NA | 331.55 | 331.55 | 331.55 | 331.55 |
Cash at End of Period | NA | 99.92 | 62.06 | 77.20 | 113.31 |
Diluted Net EPS | NA | -5.73 | -5.34 | -4.69 | -4.23 |